Literature DB >> 9781685

Sequence specific cleavage of the HIV-1 coreceptor CCR5 gene by a hammer-head ribozyme and a DNA-enzyme: inhibition of the coreceptor function by DNA-enzyme.

R Goila1, A C Banerjea.   

Abstract

The chemokine receptor CCR5 is used as a major coreceptor for fusion and entry by non-syncytia inducing macrophage tropic isolates of HIV-1, which is mainly involved in transmission. Individuals who are homozygous for the delta32 allele of CCR5 are usually resistant to HIV-1 infection and continue to lead a normal healthy life. Thus this gene is dispensable and is, therefore, an attractive target in the host cell for interfering specifically with the virus-host interaction. With the aim to develop a specific antiviral approach at the molecular level, we have synthesized a hammer-head ribozyme and a DNA-enzyme. Both ribozyme and DNA-enzyme cleaved the CCR5 RNA in a sequence specific manner. This cleavage was protein independent but Mg2+ dependent. The extent of cleavage increased with increasing concentration of magnesium chloride. DNA-enzyme was more effective in cleaving a full length (1376 bases) in vitro generated transcript of CCR5 gene. In this communication, we show that the DNA-enzyme when introduced into a mammalian cell, results in decreased CD4-CCR5-gp160 mediated fusion of cell membranes. Potential applications of these trans acting molecules are discussed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9781685     DOI: 10.1016/s0014-5793(98)01137-5

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  16 in total

1.  Inhibition of hepatitis B virus X gene expression by novel DNA enzymes.

Authors:  R Goila; A C Banerjea
Journal:  Biochem J       Date:  2001-02-01       Impact factor: 3.857

Review 2.  Catalytic DNAs as potential therapeutic agents and sequence-specific molecular tools to dissect biological function.

Authors:  L M Khachigian
Journal:  J Clin Invest       Date:  2000-11       Impact factor: 14.808

3.  In vitro-selected RNA cleaving DNA enzymes from a combinatorial library are potent inhibitors of HIV-1 gene expression.

Authors:  B Sriram; A C Banerjea
Journal:  Biochem J       Date:  2000-12-15       Impact factor: 3.857

4.  Ribozymes that cleave reovirus genome segment S1 also protect cells from pathogenesis caused by reovirus infection.

Authors:  S Shahi; G K Shanmugasundaram; A C Banerjea
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-13       Impact factor: 11.205

5.  Gene silencing of HIV chemokine receptors using ribozymes and single-stranded antisense RNA.

Authors:  Amer Qureshi; Richard Zheng; Terry Parlett; Xiaoju Shi; Priyadhashini Balaraman; Sihem Cheloufi; Brendan Murphy; Christine Guntermann; Peter Eagles
Journal:  Biochem J       Date:  2006-03-01       Impact factor: 3.857

6.  Genetic factors for aids progression: Analyses of HIV-1 resistant genes in India and therapeutic potentials of novel catalytic RNA and DNA molecules.

Authors:  Samitabh Chakraborti; Akhil C Banerjea
Journal:  Indian J Clin Biochem       Date:  2002-07

7.  Inhibition of HIV-1 gene expression by novel macrophage-tropic DNA enzymes targeted to cleave HIV-1 TAT/Rev RNA.

Authors:  H Unwalla; A C Banerjea
Journal:  Biochem J       Date:  2001-07-01       Impact factor: 3.857

8.  Inhibition of HIV-1 Integrase gene expression by 10-23 DNAzyme.

Authors:  Nirpendra Singh; Atul Ranjan; Souvik Sur; Ramesh Chandra; Vibha Tandon
Journal:  J Biosci       Date:  2012-07       Impact factor: 1.826

9.  Solution NMR Spectroscopy as a Tool to Study DNAzyme Structure and Function.

Authors:  Jan Borggräfe; Manuel Etzkorn
Journal:  Methods Mol Biol       Date:  2022

10.  Electroporation-mediated delivery of catalytic oligodeoxynucleotides for manipulation of vascular gene expression.

Authors:  Elizabeth A Nunamaker; Hai-Ying Zhang; Yuichi Shirasawa; Joseph N Benoit; David A Dean
Journal:  Am J Physiol Heart Circ Physiol       Date:  2003-07-24       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.